- Home
- CTRM vs GTBP Comparison
CTRM vs GTBP Comparison
Compare CTRM & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTRM | GTBP |
|---|---|---|
| Founded | 2016 | 1965 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 12.4M |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CTRM | GTBP |
|---|---|---|
| Price | $1.29 | $3.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 38.9K | ★ 69.3K |
| Earning Date | 12-02-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.25 | $0.22 |
| 52 Week High | $2.66 | $236.00 |
Technical Indicators
Market Signals| Indicator | CTRM | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 28.38 | 28.32 |
| Support Level | $1.25 | $0.22 |
| Resistance Level | $2.44 | $7.50 |
| Average True Range (ATR) | 0.09 | 0.39 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 15.62 | 4.37 |
Price Performance
Historical ComparisonAbout CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments, namely (i) the dry bulk segment, (ii) the containership segment, and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.